INTRODUCTION
Antimicrobial drugs applied topically offer several advantages over systemic administration, including avoidance of systemic toxicity and side effects, the decreased induction of bacterial resistance, high local concentration of antibacterial agents and low costs. 1 Moreover, the broad use of this class of drugs is largely the result of self-prescription of over-the-counter preparations containing antibiotics, including ointments, eye-drops and otological solutions, uses that are supported by little or no scientific evidence. 2 Staphylococcus aureus is the major causative agent of skin and soft tissue infections and treatment of S. aureus infections has become more difficult with time due to the emergence of multidrug-resistant strains. 3 Atopic dermatitis (AD) is a chronic skin condition that has been strongly linked to the presence of S. aureus, while cutaneous infection constitutes an important mechanism of worsening disease. 4 Thus, patients are frequently prescribed or self-prescribe antimicrobial medication, often topical preparations of antimicrobials associated with corticosteroids.
However, there is growing concern over resistance to topical antimicrobials. 5 Some of these drugs, such as fusidic acid, can also be used systemically in the treatment of methicillin-resistant S.
aureus (MRSA) infections. 6, 7 Employing topical preparations in superficial infections and a variety of inflammatory dermatosis, including AD, has been deemed responsible for the emergence of fusidic acid-resistant S. aureus (FRSA) strains. Some authors have called for its topical use to be restricted or even abolished. 8, 9 Nevertheless, mupirocin can only be administered topically and its efficacy on S. aureus carriage eradication has disseminated its use for nasal decolonization. 10 High-level mupirocin resistance, defined by minimum inhibitory concentration (MIC) ≥256µg/mL, has been increasingly reported and has emerged as a significant problem. 
METHODS

Patients and isolates
We conducted a cross-sectional study of children and adults diagnosed with AD who consecutively attended two outpatient dermatologic clinics in Porto Alegre, southern Brazil, over a oneyear period (December 2009 to December 2010). The diagnosis of AD was made by the treating dermatologist, based on standard criteria. 16 Patients who had at least one dermatitis lesion at the time The only statistically significant association detected was between the EASI score and fusidic acid resistance (the greater the severity of AD, the higher the probability of colonization by FRSA, p=0.009).
Since testing neomycin susceptibility using a 30µg disk diffusion assay was not standardized, we performed an ROC curve analysis and set a value of ≥16mm for the inhibition zone diameter to define susceptibility (according to the MIC reference) (Graph 2). Regarding aminoglycoside cross-resistance, our logistic regression model did not demonstrate an association between gentamicin and neomycin resistance (p=0.896), adjusted by demographic and medical variables (Table 3) .
DISCUSSION
This study evaluated the in vitro susceptibility of S. aureus to commonly used topical antimicrobials. Our data, from a southern Brazilian sample of AD patients, showed a low prevalence of mupirocin and fusidic acid resistance among S. aureus atopic eczema colonizer strains. All our strains were MSSA, but a previous study of MRSA carriers from an intensive care unit in Porto Alegre also demonstrated low levels of mupirocin resistance. 23 MIC determination confirmed low levels of fusidic acid resistance in our sample. Clinical and laboratorial evidence support the hypothesis that the selection of naturally occurring mutant S.
aureus is an important mechanism of fusidic acid resistance when exposed to the drug. 24 Alsterholm et al. conducted a study on Sweden and found high proportions of FRSA in impetigo (as high as 75%) but a significantly lower prevalence (6.1%) was detected in
Resistance was defined by: * historical MIC breakpoints; ** CLSI standard 10µg disk diffusion assay; § BSAC breakpoint on 5µg disk diffusion assay; ¶ EUCAST MIC breakpoints; ‡ BSAC breakpoint on 10µg disk diffusion assay; £ EUCAST breakpoint on 10µg disk diffusion assay.
MIC50 and MIC90 were defined as the minimum inhibitory concentrations encompassing 50 and 90% of isolates tested, respectively. infected atopic dermatitis. 25 Some authors hypothesized that the impetigo clone, described as being responsible for impetigo outbreaks in Europe, is not a frequent atopic dermatitis colonizer. 26 In
In Brazil, this low prevalence of resistance can also be explained by low use of topical mupirocin and fusidic acid. Products containing these drugs are relatively expensive and unavailable in the Brazilian public health system. In contrast, an ointment containing neomycin and bacitracin is a cheap and highly popular product, widely used as self-prescription medication for small wounds, insect bites and a variety of cutaneous infectious and inflammatory conditions, including AD. This can explain our high levels of neomycin and bacitracin resistance. All strains in our study were resistant to bacitracin according to a historical breakpoint and the MIC 50 was considerably high (96 µg/ml). Our results also corroborate the literature about the absence of cross-resistance between neomycin and gentamicin, although an in vitro study has demonstrated that aminoglycoside resistance stability in S. aureus is closely linked to the resistance of strains to neomycin. 27, 28 For many years, the utility and importance of topical antimicrobials has been underestimated. With the emergence of multidrug resistant strains, like community acquired MRSA infections (CA-MRSA), any agent with an antistaphylococcal activity plays an important role in the limited armamentarium against these microorganisms, especially if the drug can also combat severe systemic infections, as fusidic acid does. 12, 29 In the literature, there is growing evidence of numerous clinical benefits of topical applied antibiotics (apart from impetigo treatment), notably S. aureus decolonization.
In AD patients, despite a recent randomized placebo controlled study that suggested the efficacy of antiseptics and mupirocin in decreasing the clinical severity of the disease, pooled evidence failed to demonstrate that antimicrobial administration (topical or systemic) aimed at reducing S. aureus colonization is clinically useful. [30] [31] [32] [33] [34] However, the benefit of mupirocin use for S. aureus decolonization in other clinical circumstances has been demonstrated by many other studies. Intranasal mupirocin was associated with a significant reduction in surgical-site infections and proven to be a cost-effective approach in prosthetic orthopedic surgery. 35, 36 A systematic review showed a significant reduction in S. aureus nosocomial infections associated with intranasal mupirocin decolonization. 37 Nonetheless, reports of S. aureus mupirocin resistance associated with eradication treatment have raised concerns over continued clinical efficacy. 38 Clinical evidence demonstrates that judicious use to decolonize identified nasal carriers without S. aureus active infection should reduce resistance levels. 39 As S. aureus decolonization clinical benefits become relevant and mupirocin becomes less active, studies of alternatives are necessary. Resistance to neomycin, bacitracin and polymyxin B was found to be rare in the USA, despite its long period of over-the-counter sales. 27 A small study described successful MRSA decolonization using a triple compound (bacitracin, polymyxin B and gramicidin) in 9 out of 11 patients. 40 The clinical significance of this in vitro study of topical antimicrobial resistance is uncertain and debate persists about appropriate breakpoints for susceptibility in laboratory testing. A topical product with a widely published breakpoint is mupirocin -susceptible at MIC≤1µg/mL and high-level resistance at MIC≥256µg/ mL. 18 Experts believe that only high-level mupirocin resistance may have clinical significance, and this breakpoint corresponds to an approximate 1:100 dilution of the marketed product. 27 However, initial evidence shows that low-level mupirocin resistance combined with a genotypic chlorhexidine resistance significantly increases the failure of MRSA decolonization therapy. 41 With the exception of mupirocin, breakpoints used for topical antibiotic susceptibility testing are not widely available. Neomycin and bacitracin historical breakpoints used in this study were selected to predict success in treating systemic infections at lower in vivo concentrations, not for treating superficial infections at higher concentrations. 19,20 Bacitracin employment in systemic infections proved limited early due to its high nephrotoxicity, while neomycin was withdrawn following the development of less toxic aminoglycosides. 1, 20 This lack of standardization compromises topical antimicrobial resistance research and monitoring. In the absence of standardization, we considered neomycin historical MIC breakpoints and proposed an inhibition zone diameter of 16mm to define resistance by using a 30µg neomycin disk to routinely monitor neomycin resistance in laboratory centers. Due to the 100% bacitracin resistance we found, it was not possible to establish a breakpoint for the bacitracin disk diffusion routine test.
CONCLUSIONS
Our data, from a southern Brazilian sample of AD patients, showed a low prevalence of mupirocin and fusidic acid resistance of S. aureus atopic eczema colonizer strains. However, for neomycin and bacitracin, commonly used topical antimicrobial drugs in Brazil, high levels of resistance were found. Although based on the an-A value of 16.5mm of inhibition zone diameter corresponded to the best breakpoint regarding sensitivity and specificity to define S. aureus susceptibility to neomycin by disk diffusion technique, using a 30µg neomycin disk. 
